• Explore /
  • Poster
  • / RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

Abstract Video & Slides Poster

Authors

null

Lin Shen

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China

Lin Shen , Ken Kato , Sung-Bae Kim , Jaffer A. Ajani , Kuaile Zhao , Zhiyong He , Xinmin Yu , Yongqian Shu , Qi Luo , Jufeng Wang , Zhendong Chen , Zuoxing Niu , Jong Mu Sun , Chen-Yuan Lin , Hiroki Hara , Roberto Pazo-Cid , Christophe Borg , Liyun Li , Aiyang Tao , Eric Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03430843

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4012)

DOI

10.1200/JCO.2021.39.15_suppl.4012

Abstract #

4012

Abstract Disclosures

Similar Posters

First Author: Eric Van Cutsem

First Author: Kuaile Zhao

First Author: Makoto Endo

First Author: Manish A. Shah